RSLS - Pambiji Buku Bisnis ReShape Lifesciences Inc

Poor management competence at ReShape Lifesciences (RSLS) leads to a constant shortage of funds and additional share issuances, as confirmed by the GURU.Markets quotes provided below, where the metric stands at 0.01. Business stability relies on US plants and FDA support. Meanwhile, ReShape Lifesciences (RSLS) is developing minimally invasive weight loss systems, integrating telemedicine software into its devices and updating its engineering base.

RSLS Kapitalisasi Buku ReShape Lifesciences Inc. (04.07.2022 - 30.08.2025)

Rincian metrik lan analitis perusahaan ReShape Lifesciences Inc (RSLS)

- rega lan prakiraan konsensus rega:

Bagan rega ReShape Lifesciences|RSLS - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar ReShape Lifesciences, Inc.|RSLS - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Rega Buku Saham ReShape Lifesciences|RSLS - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku reshapelifesciences.com|RSLS - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal ReShape Lifesciences|RSLS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal ReShape Lifesciences|RSLS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku ReShape Lifesciences, Inc.

Pambiji fundamental perusahaan:ReShape Lifesciences Inc. - RSLS

Sales of specialized obesity treatment devices drive the capital inflow reflected in the book value of ReShape Lifesciences (RSLS) net assets as the difference between all assets and liabilities. This indicator's trend allows investors to assess the actual accounting stability of ReShape Lifesciences, identifying hidden capital erosion or the growth of internal business reserves regardless of market price fluctuations.

Analisis perusahaan pesaing